IBM (IBM) Q3 2024 Earnings Call Transcript

IBM reported Q3 revenue of $15.0B, up 2% at constant currency, with software revenue accelerating 10% and Red Hat up 14%, offset by consulting being flat and infrastructure down 7%. Management raised confidence in 2025 growth, citing more than $3B of generative AI bookings, $6.6B of year-to-date free cash flow, and an increased $3.5B annual run-rate savings target. Operating pretax margin expanded 100 bps and full-year free cash flow is still expected to exceed $12B.

Analysis

IBM is increasingly behaving like a quality software compounder wrapped in a legacy hardware wrapper: the mix shift plus recurring revenue growth is compressing the cyclicality premium that has historically capped the multiple. The key second-order effect is that every incremental dollar of software/AI revenue now carries a higher probability of converting into durable FCF than headline growth alone implies, so the market should start valuing IBM less like a low-growth IT services vendor and more like a mid-teens-margin software platform with an annuity overlay.

The near-term pressure point is Consulting. What looks like weakness is partly a yield issue, not just demand destruction: longer-duration GenAI work is displacing faster-turn, higher-yield discretionary projects. That means reported revenue can lag bookings by 2-4 quarters, creating a window where sentiment stays muted even as backlog quality improves; this is exactly the setup that can generate upside surprise in 2H25 if conversion accelerates.

Competitive spillovers matter. IBM’s cost-optimized small-model strategy is a direct challenge to hyperscaler-first, scale-at-all-costs AI economics and should help it win regulated enterprise workloads where ROI and licensing control matter more than frontier capability. That positioning is constructive for Dell, SAP, and parts of Oracle/CRM ecosystem partnerships, but it raises the bar for MSFT/AMZN monetization assumptions at the enterprise edge if customers increasingly demand lower-cost, task-specific inference instead of broad model usage.

The contrarian risk is that management’s 2025 inflection thesis may already be embedded if investors buy the story before consulting conversion shows up. The biggest watch item over the next 3-6 months is whether the mainframe cycle and software momentum can offset another quarter or two of consulting softness without requiring multiple expansion; if not, the stock may remain range-bound until actual revenue acceleration appears. The upside case is that FCF continues to outrun revenue, forcing a rerating even before growth clearly reaccelerates.

Key Decisions for Investors

• Long IBM vs short IT or a basket of legacy IT services names for 3-6 months: IBM has a cleaner path to FCF expansion and software mix improvement, while peers remain more exposed to discretionary consulting weakness.
• Buy IBM Jan-2026 calls on pullbacks rather than after strength: the setup is a delayed 2H25 conversion story, so entry should favor periods when the market prices in another soft consulting quarter.
• Pair trade long IBM / short a hyperscaler AI monetization proxy such as MSFT if enterprise AI spend starts shifting toward task-specific, lower-cost models; risk is that frontier-model attach rates remain dominant longer than expected.
• If IBM trades up sharply before consulting signings turn, take partial profits or hedge with short-dated calls against the long: the consensus may front-run the 2025 inflection before revenue evidence arrives.
• Watch DELL as a secondary beneficiary over the next 6-12 months: IBM’s enterprise AI deployment model favors infrastructure partners that help deliver lower-cost inference at scale, but only if customer adoption moves from pilot to production.